Q2 Earnings Forecast for ImmunityBio Issued By HC Wainwright

ImmunityBio, Inc. (NASDAQ:IBRX) – Equities research analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for ImmunityBio in a report issued on Monday, May 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.12 EPS and FY2029 earnings at $0.34 EPS.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The company had revenue of $16.52 million during the quarter, compared to the consensus estimate of $17.50 million.

Separately, D. Boral Capital restated a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research note on Monday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $12.19.

ImmunityBio Stock Up 7.2%

ImmunityBio stock opened at $2.67 on Thursday. The business has a 50-day simple moving average of $2.64 and a two-hundred day simple moving average of $3.32. The company has a market cap of $2.36 billion, a P/E ratio of -2.90 and a beta of 0.33. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $8.16.

Institutional Trading of ImmunityBio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Slow Capital Inc. bought a new stake in ImmunityBio during the first quarter valued at about $30,000. Compound Planning Inc. purchased a new position in shares of ImmunityBio in the first quarter worth about $30,000. Thrive Wealth Management LLC purchased a new position in ImmunityBio during the first quarter valued at approximately $30,000. Stephens Inc. AR purchased a new position in ImmunityBio during the fourth quarter valued at approximately $26,000. Finally, Xponance Inc. purchased a new position in ImmunityBio during the first quarter valued at approximately $33,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.